Join us this June to raise awareness, attend events, fundraise, and celebrate 50 years of myaware supporting the myasthenia community. Read more
Click to read more Read more
Great fundraising starts with small ideas. Check out our new Fundraising Guide, packed full of simple, realistic ideas that anyone can try. Download
500,000 people have been forgotten and left behind, unfairly affected by Covid. Many are still shielding, still in isolation. Still unable to work, see friends or hug loved ones. Evusheld offers them the chance to live a more normal and free life. Read more
In 2025, the government announced several benefit changes due over the next few years. This page explains the main reforms and when they are expected to happen. Read more
Rozanolixizumab has become the first targeted therapy to be approved for the treatment of refractory generalised myasthenia gravis and will be eligible for reimbursement via NHS England. Read more
Learn more about an actively recruiting study that is using patient voices to better understand fatigue in generalised myasthenia gravis. Read more
Read more about the current meningitis B outbreak and guidance for myasthenia patients. Read more
The SMC has released negative guidance for the medicine Zilucoplan. Learn more about this process and next steps. Read more
Learn more about this treatment method which is being explored in myasthenia gravis patients. Read more
Dr Dodd, Consultant Neurologist at Manchester Centre for Clinical Neuroscience published a research study “Immune profiles in myasthenia gravis”, part funded by myaware. This project aimed to examine circulating immune markers in those with myasthenia gravis (MG) of different treatment requirements, and myaware funding allowed detailed analysis of circulating T cells as part of the study. Read more
Find out more about our successful appeal against NICE's decision to issue negative guidance for the drug zilucoplan. Read more
Take on a brilliant running challenge and make every mile count for people living with Myasthenia Gravis. Read more
An insightful and engaging online program for healthcare professionals, including patient education guides and freely available CME credits. Read more
Read more about the current changes to the MMR vaccine and how this affects immunosuppressed patients. Read more
Read more about our stance on NICE's decision to release negative final draft guidance for zilucoplan, a new medicine for myasthenia gravis. Read more
Self-advocacy is the ability to speak up for yourself, express personal needs, make informed decisions, and take action to ensure that your rights and preferences are respected Read more
Find out more about what other countries are doing to raise awareness of myasthenia in June. Read more
The European Myasthenia Gravis Association (EuMGA) has written in support of myaware and our efforts in bringing access to innovative care for patients in the UK. Read more
This information is designed to provide guidance on symptom management for myasthenia patients in the event of exacerbation or flare of their disease. It also includes information on myasthenic crisis. Read more
This My Awareness Month, we’re focusing on Self-Advocacy. Read more
Read our statement on the disappointing news that efgartigimod will not be made available to patients in England on the NHS. Read more
Living with myasthenia can bring daily challenges, and learning to advocate for yourself with friends and family is a key part of managing your condition. Read more
For carers, those who provide unpaid care and support to a family member or friend, self-advocacy is essential but often overlooked. Read more
Self-advocacy in the welfare system means speaking up for your needs, understanding your rights, and ensuring you get the financial support, fair treatment and help you're entitled to. Read more